These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25467958)

  • 1. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
    Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
    Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
    Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
    AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
    Chang HP; Cheung YK; Liu S; Shah DK
    Br J Clin Pharmacol; 2024 Jul; 90(7):1637-1655. PubMed ID: 38566392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.
    Lu D; Gibiansky L; Agarwal P; Dere RC; Li C; Chu YW; Hirata J; Joshi A; Jin JY; Girish S
    CPT Pharmacometrics Syst Pharmacol; 2016 Dec; 5(12):665-673. PubMed ID: 27863168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
    Chang HP; Li Z; Shah DK
    Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.
    Singh AP; Shah DK
    Drug Metab Dispos; 2017 Nov; 45(11):1120-1132. PubMed ID: 28821484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
    Li C; Zhang C; Li Z; Samineni D; Lu D; Wang B; Chen SC; Zhang R; Agarwal P; Fine BM; Girish S
    MAbs; 2020; 12(1):1699768. PubMed ID: 31852341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monomethyl auristatin E (MMAE), a payload for multiple antibody drug conjugates (ADCs), demonstrates differential red blood cell partitioning across human and animal species.
    Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
    Xenobiotica; 2024 Aug; 54(8):511-520. PubMed ID: 38647387
    [No Abstract]   [Full Text] [Related]  

  • 11. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
    Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
    Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
    Li H; Han TH; Hunder NN; Jang G; Zhao B
    J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
    Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
    MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
    Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
    Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY
    Yip V; Lee MV; Saad OM; Ma S; Khojasteh SC; Shen BQ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33806916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.